[Comparative aspects of using neuroprotectors in the management of patients with ischemic stroke].
Comparative efficacy of neuroprotective preparations: actovegin, cerebrolysin and ceraxon was studied in 73 patients in the most acute phase of ischemic stroke. A control group included 33 patients in the most acute phase of ischemic stroke who received only basic treatment without neuroprotectors. Patient's state was assessed with the NIHSS, the original scale of E.I. Gusev and V.I. Skvortsova and the Barthel index. Ceraxon in daily dosage 2 g and cerebrolysin in daily dosage 10 ml during 10 days after the development of ischemic stroke led to the significantly better regression of neurological symptoms to the 21st day of disease compared to the control group. Barthel index scores did not differ in the groups studied.
V I
VI
Ershov
D000328:Adult; D000368:Aged; D000596:Amino Acids / Q000627:therapeutic use; D003566:Cytidine Diphosphate Choline / Q000627:therapeutic use*; D005260:Female; D006418:Heme / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome
D000596:Amino Acids; D018696:Neuroprotective Agents; C006952:cerebrolysin; D006418:Heme; D003566:Cytidine Diphosphate Choline; C015646:Actovegin